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ally progress to osteoarthritis (OA), a leading cause of disability
in humans. MicroRNAs (miRNAs) can regulate the differenti-
ation of human bone marrow-derived mesenchymal stem cells
(hBMSCs) and play important roles in the expression of genes
related to OA. However, their functional roles in OA remain
poorly understood. Here, we have examined miR-449a, which
targets sirtuin 1 (SIRT1) and lymphoid enhancer-binding fac-
tor-1 (LEF-1), and observed its effects on damaged cartilage.
The levels of chondrogenic markers and miR-449a target
genes increased during chondrogenesis in anti-miR-449a-
transfected hBMSCs. A locked nucleic acid (LNA)-anti-miR-
449a increased cartilage regeneration and expression of
type II collagen and aggrecan on the regenerated cartilage sur-
face in acute defect and OA models. Furthermore, intra-artic-
ular injection of LNA-anti-miR-449a prevented disease pro-
gression in the OA model. Our study indicates that miR-449a
may be a novel potential therapeutic target for age-related joint
diseases like OA.Received 11 January 2018; accepted 23 September 2018;
https://doi.org/10.1016/j.omtn.2018.09.015.
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Traumatic and degenerative lesions of articular cartilage usually
progress to osteoarthritis (OA), which is the most prevalent joint
disease and a leading cause of disability. In particular, cartilage dis-
ease or injury involving damage to the articular cartilage is a
serious problem due to limitations in self-repair capacity.1 There-
fore, various treatments have been developed to prevent cartilage
degeneration and restore injured cartilage, such as microfracture,
stem cell therapy, and implantation of autologous chondrocytes
or bone marrow concentrates.2–4 Human bone marrow-derived
mesenchymal stem cells (hBMSCs) have self-renewal capacity
and are multipotent, with the capacity to differentiate into chon-
drocytes.5,6 Therefore, stem cell therapy using hBMSCs is a good
option for the regeneration of damaged cartilage. Recent studies
have reported that a three-dimensional scaffold that includes322 Molecular Therapy: Nucleic Acids Vol. 13 December 2018 ª 2018
This is an open access article under the CC BY-NC-ND license (httphBMSCs can replace damaged tissue, leading to cartilage restora-
tion, and when combined with cartilage-related cytokines can
secrete autologous cells, enhancing the repair of damaged carti-
lage.7–9 Additionally, intra-articular injection of hBMSCs can
stimulate anti-inﬂammatory genes and inhibit the expression of
catabolic genes such as matrix metalloproteinases (MMPs).10 How-
ever, long-term expansion of hBMSCS in vitro has many limita-
tions, such as loss of stemness and differentiation capacity. Due
to this, various cell-based techniques have been attempted, using
diverse cell sources such as induced pluripotent stem cells (iPSCs)
and gene therapy strategies with chondrogenesis-related genes.11–13
However, these techniques have not yet been completely estab-
lished, and these challenges remain unsolved in vivo. Limitations
in hBMSC transplantation also remain, including inefﬁcient deliv-
ery, safety issues, difﬁculties in producing tissue of normal
morphology, and a limited supply of healthy articular cartilage
because of surgical removal.14–16 Additionally, there are few in vivo
studies examining the prevention of OA progression using stem
cells.
MicroRNAs (miRNAs) are small non-coding RNAs that regulate
gene expression through post-transcriptional or post-translational
regulation in various biological processes and diseases.17,18 The
miRNAs have many beneﬁts that have mature sequences as short
and completely conserved targeting multiple vertebrate species.19
Therefore, gene modulation therapy using miRNAs has emergedThe Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Effect of miR-449a on the In Vitro
Chondrogenic Differentiation of hBMSCs
(A) Relative miR-449a expression during the chondro-
genic differentiation of hBMSCs mass culture as deter-
mined by real-time qPCR. U6 was used for normalization.
(B) Relative mRNA level of chondrogenic marker gene
COL2A1 during chondrogenic differentiation of hBMSCs
mass culture as determined by real-time qPCR. ACTB
was used for normalization. (C–F) Relative mRNA levels of
chondrogenic marker genes such as SOX9 (C), ACAN (D),
and the miR-449a target genes such as SIRT1 (E) and
LEF1 (F) during 5 days of chondrogenic differentiation.
ACTBwas used for normalization. (G) The protein levels of
chondrogenic markers andmiR-449a target genes during
10 days of chondrogenic differentiation. GAPDH was
used as a loading control. Data are defined asmean ± SD.
p values were calculated compared with controls. *p <
0.05; **p < 0.01; ***p < 0.001 (n = 3 independent exper-
iments).
www.moleculartherapy.orgas a potential therapeutic candidate against a variety of dis-
eases.20–22 Gene therapy strategies based on miRNAs have been
applied to cancers both experimentally and clinically.23,24 Several
studies have reported that certain miRNAs are aberrantly ex-
pressed in patients with OA, indicating that miRNAs play an
important role in cartilage development.25,26 Recent in vitro studies
have revealed that inhibition of miR-138-5p promotes interleukin-
1b (IL-1b)-induced cartilage destruction in human chondrocytes
by targeting FOXC1,27 whereas miR-92a-3p regulates cartilage
development and homeostasis in hBMSCs by targeting histone de-
acetylase 2.28 miR-140-5p inhibits mediators of inﬂammation and
promotes chondrogenesis in IL-1b-induced human chondrocytes,
and plays roles in both cartilage development and homeostasis in
miR-140-deﬁcient mice and cartilage-speciﬁc miR-140 transgenic
mice.29,30 Recent in vivo studies have revealed that inhibition of
miR-221 in hBMSCs promotes cartilage regeneration.31 Another
group revealed that intra-articular injection of antago-miR-483-
5p blocks OA by targeting the cartilage matrix protein matrilin 3
and tissue inhibitor of metalloproteinase 2.32 However, the rolesMolecular Therapof miRNAs as gene modulators during carti-
lage regeneration and OA prevention remain
largely unknown.
Our group has previously demonstrated that
miR-449a regulates hBMSC chondrogenesis by
targeting lymphoid enhancer-binding factor 1
(LEF1).33 We also revealed that miR-449a regu-
lates expression of sirtuin 1 (SIRT1) during IL-
1b-induced cartilage destruction, which pro-
motes OA.34 Another group reported that
SIRT1 has an anabolic effect in chondrocytes
and promotes the chondrogenic differentiation
of hBMSCs.35 Taken together, these reports
indicate that miR-449a regulates the chondro-genesis of hBMSCs and may be a useful regulator and therapeutic
agent for the treatment of damaged cartilage.
To examine in vivo miR-449a function, we utilized a locked nucleic
acid (LNA) to stably deliver the miRNA and enhance its function.
The LNA is a modiﬁed RNA nucleotide with an extra bridge linking
the 20 oxygen and 40 carbon, which confers improved stability against
endonucleases and exonucleases in vivo and effective coherence with
the complementary strand.36 LNA-modiﬁed miRNAs have been
developed for potential applications in tumor diagnosis and treat-
ment.37–41 However, there are few studies on cartilage regeneration
using LNA-modiﬁed miRNA-based gene therapies.34
In this study, we have investigated the function of miR-449a in the
regulation of hBMSC chondrogenic differentiation during cartilage
regeneration using an LNA-modiﬁed miRNA as a delivery system
in rat acute defect and OA models. We demonstrate that miR-449a
enhances cartilage regeneration in an acute defect model and prevents
cartilage degeneration in an OA model by targeting LEF1 and SIRT1.y: Nucleic Acids Vol. 13 December 2018 323
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Figure 2. miR-449a Inhibits hBMSC Chondrogenic Differentiation
(A) Histological analysis using Alcian blue and safranin O staining during chondro-
genic hBMSC micromass cultures at day 10. (B) IHC analysis of COL2A1 (phyco-
erythrin [PE]; red fluorescence) and ACAN (fluorescein isothiocyanate [FITC]; green
fluorescence) with DAPI counterstaining 10 days after induction of chondrogenic
differentiation. As a control, hBMSCs treated with TGF-b3 were used. Scale bars,
500 mm (original magnification 4). The data were confirmed in cells from three
independent donors, and representative data are shown.
Molecular Therapy: Nucleic AcidsCollectively, these results indicate that anti-miR-449a is a promising
and novel therapeutic target for OA and general cartilage damage.
RESULTS
Effect of miR-449a on hBMSC Chondrogenesis
To investigate the effects of miR-449a, we observed the expression
of miR-449a by miR-speciﬁc real-time qPCR at various time points
during chondrogenic differentiation of hBMSCs micromass cul-
ture. The results showed that the miR-449a expression was contin-
uously expressed and remained upregulated after induction of
chondrogenesis differentiation (Figure 1A). Additionally, the
expression levels of chondrogenic marker type II collagen
(COL2A1) were also upregulated (Figure 1B). Next, we analyzed
the mRNA levels of chondrogenic differentiation marker genes
and miR-449a target genes, such as SRY-related high mobility
group-box gene 9 (SOX9), aggrecan (ACAN), SIRT1, and LEF1 by
real-time qPCR. The expression levels of chondrogenic differentia-
tion marker genes were signiﬁcantly decreased in miR-449a-trans-
fected hBMSCs compared with miR-sc (control)-transfected
hBMSCs. Conversely, the expression of these genes was signiﬁ-
cantly increased in anti-miR-449a-transfected hBMSCs compared324 Molecular Therapy: Nucleic Acids Vol. 13 December 2018with anti-miR-sc-transfected hBMSCs (Figures 1C–1F). Further-
more, the expression levels of the miRNA-449a target genes
SIRT1 and LEF1 were consistently and signiﬁcantly decreased in
miR-449a-transfected hBMSCs, and signiﬁcantly increased in
anti-miR-449a-transfected hBMSCs (Figures 1C–1F). The protein
levels showed consistent trends (Figure 1G).
Finally, we conﬁrmed the effects of miR-449a on chondrogenesis by
histological analysis using Alcian blue and safranin O staining and
immunohistochemistry (IHC). With Alcian blue, anti-miR-449a-
transfected hBMSCs were the most positively stained (Figure 2A).
With safranin O staining, the synthesis of proteoglycans was mostly
increased in anti-miR-449a-transfected hBMSCs (Figure 2A). More-
over, the mass was larger in anti-miR-449a-transfected hBMSCs than
in anti-miR-sc-transfected and control hBMSCs (Figure 2A). By IHC
analysis, COL2A1 and ACAN expression levels were decreased in
miR-449a-transfected hBMSCs (Figure 2B). However, anti-miR-
449a-transfected hBMSCs displayed increased COL2A1 and ACAN
expression (Figure 2B). Taken together, these results indicate that
miR-449a negatively regulates the chondrogenic differentiation of
hBMSCs.
Establishment of Optimal LNA-Anti-miR-449a Concentration
To determine the effects of miR-449a on hBMSC chondrogenic dif-
ferentiation during cartilage regeneration, we used LNA-anti-miR-
449a, both as a delivery system and to improve the efﬁciency of
miR-449a functional inhibition. We synthesized LNA-anti-miR-
449a, with antisense oligonucleotides complementary to miR-449a
(Figure 3A), and ﬁrst investigated whether the synthesized LNA
was cytotoxic in hBMSCs by 3-[4, 5-dimethylthiazol-2-yl]-2, 5 di-
phenyl tetrazolium bromide (MTT) assay. LNA-anti-miR-sc and
LNA-anti-miR-449a had no effect on cell viability at all tested con-
centrations (Figure 3B). To establish the optimal concentration of
LNA-anti-miR-449a in terms of improved target gene expression
and inhibition of miR-449a expression, we treated hBMSCs with
LNA-anti-miR-scramble control (LNA-anti-miR-sc) or LNA-anti-
miR-449a in a dose-dependent manner and analyzed miRNA
expression levels using miR-speciﬁc real-time qPCR. When
hBMSCs were treated with 10–500 nM LNA-anti-miR-449a, miR-
449a expression was inhibited by 50–100 nM LNA-anti-miR-449a,
compared with hBMSCs treated with LNA-anti-miR-sc (Figure 3C).
Next, we examined the expression of miR-449a target genes such as
LEF1 and SIRT1. When hBMSCs were treated with LNA-anti-miR-
449a, the mRNA expression increased in a dose-dependent manner
(Figure 3D), and protein expression was enhanced at concentrations
R50 nM (Figure 3E). For these reasons, we determined that the
optimal LNA-anti-miR-449a concentration for in vivo treatment
was 100 nM.
LNA-Anti-miR-449a Promotes Cartilage Regeneration in an
Acute Defect Model
To examine whether LNA-anti-miR-449a affected cartilage regen-
eration in an acute defect model, we created osteochondral defects
in rats, and the defect sites were either left untreated or ﬁlled with
A B
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Figure 3. Synthesis of LNA-Anti-miRs and
Concentration Optimization
(A) The structure of the LNA oligonucleotides and the
sequences of the LNA-modified-anti-miR-scramble con-
trol (LNA-anti-miR-sc) and LNA-modified-anti-miR-449a
(LNA-anti-miR-449a). (B) A cytotoxicity assay was per-
formed to detect the loss of viability. (C) After treatment of
hBMSCs with various concentrations of LNA-anti-miR-sc
or LNA-anti-miR-449a, relative miR-449a levels were
measured by miR-specific qPCR. U6 was used for
normalization. (D) The mRNA levels of the miR-449a
target genes SIRT1 and LEF1 in hBMSCs after treatment
with various concentrations of LNA-anti-miR-sc or LNA-
anti-miR-449a. (E) The protein levels of the miR-449a
target genes SIRT1 and LEF1 in hBMSCs after treatment
with various concentrations of LNA-anti-miR-sc or LNA-
anti-miR-449a. Data are defined asmean ±SD. **p < 0.01
(n = 3 independent experiments).
www.moleculartherapy.orghBMSCs, hBMSCs with LNA-anti-miR-sc, or hBMSCs with LNA-
anti-miR-449a (Figure 4A). Histological analysis of regenerated
articular cartilage was performed 4 and 8 weeks after surgery. Af-
ter 4 weeks, the regenerated cartilage in the hBMSCs with LNA-
anti-miR-449a group was smooth and resembled normal cartilage
tissue (Figure 4B). However, the hBMSCs and hBMSCs with
LNA-anti-miR-sc groups showed comparatively insufﬁcient carti-
lage regeneration. Histological features were examined by H&E
and Masson’s trichrome (MT) staining, and well-differentiated
chondrocytes resembling those of normal cartilage were observed
in the hBMSCs with LNA-anti-miR-449a group (Figure 4C).
However, the other groups showed incompletely differentiated
chondrocytes and severe disruption of normal cartilage surface.
There was increased safranin O staining throughout the matrix,
with abundant glycosaminoglycans (GAGs) and intact surface
integrity in the hBMSCs with LNA-anti-miR-449a group (Figures
4D and 4E), whereas the other groups showed reduced safranin O
staining. We evaluated the histological ﬁndings using a modiﬁed
O’Driscoll score system (Figure 4F). The hBMSCs with LNA-anti-
miR-449a group showed signiﬁcantly higher scores (16.13 ± 2.77;
p = 0.0001; Figure 4F) than the defect (7.65 ± 1.46), hBMSCsMolecular Therap(10.14 ± 1.06), and hBMSCs with LNA-
anti-miR-sc (9.64 ± 1.28) groups, and as ex-
pected, there were no signiﬁcant differences
between these three groups. Finally, we inves-
tigated the expression of COL2A1 and ACAN
on the regenerated cartilage by IHC analysis.
The expression of COL2A1 and ACAN
was higher in the hBMSCs with LNA-anti-
miR-449a group than in the other groups
(Figure 4G). Consistent results were observed
at 8 weeks (Figure S1). Taken together,
these results suggest that LNA-anti-miR-
449a promotes the regeneration of tissue
resembling normal cartilage, improving onthe imperfect restoration resulting from the implantation of
hBMSCs alone.
LNA-Anti-miR-449a Increases Cartilage Regeneration in an OA
Model
To determine whether LNA-anti-miR-449a has regenerative effects
on damaged cartilage in an OA model, we induced OA surgically
by destabilization of the medial meniscus (DMM) in 12-week-old
rats. We induced OA for 8 weeks to establish the model, because
OA was not deﬁnitively induced 6 weeks after DMM (data not
shown). Eight weeks after DMM, intra-articular injections of
PBS, LNA-anti-miR-sc, and LNA-anti-miR-449a were performed
twice a week for up to 8 weeks (Figure 5A). In histological analysis,
the LNA-anti-miR-449a-treated group showed intact surfaces
resembling normal, well-differentiated chondrocytes, with reduced
cartilage degradation and proteoglycan loss by safranin O and MT
staining (Figure 5B). The PBS and LNA-anti-miR-sc-treated
groups showed severe cartilage degradation and irregular chondro-
cyte morphology, severe ﬁbrillation, and loss of proteoglycan,
similar to the defect group (Figure 5B). Based on histological anal-
ysis, the LNA-anti-miR-449a-treated group had signiﬁcantly lowery: Nucleic Acids Vol. 13 December 2018 325
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www.moleculartherapy.orgmodiﬁed Mankin and Osteoarthritis Research Society International
(OARSI) scores (4.00 ± 0.88 and 1.88 ± 0.83; Figure 5C) compared
with the other groups (20 weeks defect group: 6.05 ± 0.63 and
2.77 ± 0.83; 28 weeks defect group: 10.22 ± 0.69 and 6.22 ± 0.50;
PBS group: 10.00 ± 0.66 and 5.55 ± 0.50; and LNA-anti-miR-sc
group: 10.78 ± 1.54 and 5.88 ± 0.83), indicating that LNA-anti-
miR-449a had a regenerative effect on damaged cartilage. We
also performed IHC analysis using primary antibodies against
COL2A1 and ACAN. The expression of COL2A1 and ACAN
was increased on regenerated tissue in the LNA-anti-miR-449a-
treated group (Figure 5D). Additionally, the expression of inﬂam-
matory marker protein cyclooxygenase-2 (COX-2) and cartilage
degradation marker protein MMP-13 were signiﬁcantly upregu-
lated in surgically induced OA, PBS, and LNA-anti-miR-sc-treated
groups. However, the LNA-anti-miR-449a-treated group showed a
signiﬁcant decrease in their expression compared with the other
groups. Therefore, we conﬁrm the inﬂammatory state after injec-
tion of LNA-modiﬁed miRNA (Figure S2). Together, these ﬁndings
suggest that the injection of LNA-anti-miR-449a can regenerate
damaged cartilage in a rat OA model.
LNA-Anti-miR-449a Prevents Cartilage Destruction in an OA
Model
To determine whether LNA-anti-miR-449a can prevent OA pro-
gression, we induced OA by DMM in 12-week-old rats. Starting
immediately after surgery, intra-articular injections of PBS, LNA-
anti-miR-sc, and LNA-anti-miR-449a were performed twice a
week for up to 12 weeks (Figure 6A). We performed histological
analysis using safranin O and MT staining. The LNA-anti-miR-
449a-treated group maintained a relatively intact cartilage struc-
ture, with well-differentiated chondrocytes surrounding the matrix,
and intact proteoglycan (Figure 6B). However, nearly complete
cartilage destruction, including severe ﬁbrillation, proteoglycan
loss, chondrocyte clusters, and hypertrophic chondrocytes, was
observed in the defect, PBS, and LNA-anti-miR-sc-treated groups
(Figure 6B). The LNA-anti-miR-449a-treated group had distinc-
tively lower modiﬁed Mankin and OARSI scores (2.22 ± 1.26
and 1.11 ± 0.83; Figure 6C) than the other groups (24 weeks defect
group: 8.44 ± 0.69 and 4.96 ± 0.75; PBS group: 7.88 ± 0.83 and
5.66 ± 0.33; and LNA-anti-miR-sc group: 11.67 ± 1.76 and
6.74 ± 0.35). By IHC, the expression of COL2A1 and ACAN was
the most abundant in the LNA-anti-miR-449a-treated group (Fig-
ure 6D). These results demonstrate that the intra-articular injec-
tion of LNA-anti-miR-449a slows down the progression of carti-
lage degradation in a rat OA model.Figure 4. Increased Cartilage Regeneration by LNA-Anti-miR-449a in an Acute
(A) Experimental design for cartilage regeneration induced by acute osteochondral defe
analysis of osteochondral defects observed using H&E and MT staining. Scale bars, 50
observed using safranin O staining. Scale bars, 500 mm (original magnification 4) a
(F) Quantification of histology by O’Driscoll score based on safranin O staining. (G) Left: IH
in an acute defect model. Scale bar, 50 mm (original magnification 40). Right: quanti
compared with the defect group: *p < 0.05; ***p < 0.001 (n = 7 for each group).DISCUSSION
Our study is the ﬁrst to report the role of anti-miR-449a in vivo using
acute defect and OA models, and conﬁrmed positive effect that can
regenerate the damaged cartilage and slow down aggressive OA pro-
gression targeting LEF1 and SIRT1.
Previous reports have demonstrated that the intra-articular injec-
tion of hBMSCs causes no risk of immune rejection in a rat
model.42,43 Additionally, hBMSC treatment has been used exten-
sively in research and clinical trials because of the stability of
hBMSCs and their potential to replace damaged tissue.44,45 How-
ever, studies have revealed lower regenerative capacities for hBMSCs
because of the inﬂuence of culture protocols and application
methods.46,47 This observation is in agreement with our study,
because only the hBMSCs group showed less regeneration compared
with the hBMSCs with LNA-anti-miR-449a group, which had
increased cartilage regeneration in the acute defect model. This
may indicate synergistic effects between hBMSCs and LNA-anti-
miR-449a in cartilage restoration.
Only a few studies have examined the regulation of chondrogenesis by
miRNAs. They have revealed that inhibition of miR-101 prevents
cartilage degeneration by targeting SOX9 in a monoiodoacetate-
induced rat model of OA,48 and that miR-34a regulates SIRT1 expres-
sion in human osteoarthritic chondrocytes.49 Additionally, inhibition
of miR-34a promotes aggressive disease progression in a rat OA
model.49 These groups all used adenoviral vectors for successful
miRNA delivery. Viral vectors such as lentiviruses and adenoviruses
have been widely used as miRNA delivery systems; however, limita-
tions remain, including safety issues and loss of miRNA efﬁciency.19
Poly (lactide-co-glycolide) (PLGA), a polymer, has also been widely
used as an miRNA delivery system because of its low toxicity;50,51
however, its use is limited by low loading efﬁciency.52 Liposomes con-
sisting of lipid layers have been developed for miRNA delivery;53
however, these also have limitations, including toxicity and the induc-
tion of type I and type II interferons by positively charged lipids.54
Therefore, more effective miRNAs delivery systems are required. In
contrast, we used LNA-modiﬁed oligonucleotides to not only success-
fully deliver miRNAs, but also enhance miR-449a inhibition. The
LNA-modiﬁed miRNA delivery system is one of the most advanced
in vivo delivery systems. LNA can interact with complementary
miRNAs with high afﬁnity, neutralizing the targeted miRNA with
no cytotoxicity.55,56 We have demonstrated that LNA-anti-miR-
449a is successfully delivered to defect sites, where it serves dual
positive roles, regenerating damaged cartilage and preventing OADefect Model
cts. (B) Gross morphology of osteochondral defects after 4 weeks. (C) Histological
0 mm (original magnification 4). (D) Histological analysis of osteochondral defects
nd 100 mm (original magnification 20). (E) Quantification of safranin O staining.
C analysis of COL2A1 (PE; red fluorescence) and ACAN (FITC; green fluorescence)
fication of IHC analysis. Data are defined as mean ± SD. p values were calculated
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www.moleculartherapy.orgprogression by targeting LEF1 and SIRT1. Hence, our results provide
insights on the utility of LNAs as in vivo miRNA delivery systems.
In a previous report, we showed that miR-449a negatively regulates
LEF1 expression during hBMSC chondrogenesis.33 This result sug-
gested that the inhibitionofmiR-449awouldpromote the chondrogenic
differentiation of hBMSCs by increasing LEF1 expression. Here, our
in vivo study conﬁrmed that miR-449a inhibition causes the regenera-
tion of damaged cartilage in an acute defect model and OA model.
SIRT1 plays an inhibitory role in IL-1b-induced cartilage destruction
associated with OA.57,58 In a previous report, we showed that miR-
449a regulates the expression of SIRT1, which has anti-inﬂammatory
effects on OA chondrocytes.34 We conﬁrmed that the inhibition of
miR-449a has a protective effect, inhibiting the expression of catabolic
genes and restoring the expression of anabolic genes by targeting
SIRT1 during IL-1b-induced cartilage degradation. Combined with
these previous results, the in vivo results in this study suggest that
miR-449amay be a promising novel therapeutic target for the preven-
tion of cartilage degeneration.
Overall, our observations strongly indicate dual positive effects of
silencing miR-449a, regenerating damaged cartilage and preventing
OA progression by targeting LEF1 and SIRT1. These results suggest
that miR-449a could be a promising therapeutic target for OA and
other cartilage degenerative disorders.
MATERIALS AND METHODS
Culture of hBMSCs
Bone marrow aspirates were obtained from the posterior iliac crests
of 10 healthy adult donors with a mean age of 47.5 years (range: 31–
65 years), with approval from the Institutional Review Board of
Yonsei Universiy College of Medicine (IRB No. 4-2017-0232), and
all participants agreed to participation. Cells were cultured and
selected by adherence on a plastic culture plate surface, and their
validations were conﬁrmed by ﬂow cytometry as in a previous
study,59 then cultured for 7 days in DMEM-low glucose (GIBCO,
USA) with 10% fetal bovine serum (FBS; GIBCO, USA) and 1%
antibiotic-antimycotic solution (GIBCO, USA). Cells were subcul-
tured for up to three passages, and all experiments were carried
out in triplicate.
Chondrogenic Differentiation of hBMSCs
DMEM-high glucose (DMEM-HG; GIBCO, USA) with 1 anti-
biotic-antimycotic solution, 1 insulin transferrin selenium-A (ITS;
Invitrogen, Carlsbad, CA, USA), 50 mg/mL ascorbic acid (Sigma, St.
Louis, MO, USA), and 10 ng/mL transforming growth factor
(TGF)-b3 (R&D Systems; Minneapolis, MN, USA) was used for theFigure 5. Increased Cartilage Regeneration by LNA-Anti-miR-449a in an OA M
(A) Experimental design for cartilage regeneration induced by DMM. (B) Representative s
bar, 200 mm (original magnification10). (C) Histological evaluation bymodifiedMankin a
ACAN expression on the regenerated cartilage surface by IHC analysis, with DAPI count
analysis. Data are defined as mean ± SD. p values were calculated compared with thechondrogenic differentiation of hBMSCs. For micromass culture,
1  105 hBMSCs were dropped in the center of each well of a
24-well plate. After 2 hr, chondrogenic medium was added. The me-
dium was replaced every 3 days.
Cytotoxicity Assay
A cytotoxicity assay was performed using the MTT assay in
48-well plates. EZ-Cytox cell viability reagents (Daeil Lab, Seoul,
Korea) and 300 mL of fresh medium were added, and the samples
were incubated at 37C for 4 hr. The absorbance was measured at
540 nm.
Transfection of miRNA
Cells were transfected with miR-scramble control (miR-sc; Genolu-
tion, Seoul, Korea), miR-449a mimic (Genolution, Seoul, Korea),
anti-miR-sc mimic (ST Pharm, Seoul, Korea), and anti-miR-449a
mimic (ST Pharm, Seoul, Korea) at 100 nM using Lipofectamine
LTX & Plus Reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions. LNA-modiﬁed oligonucleotides
were used as a delivery system into cartilage joints, and LNA was syn-
thesized as unconjugated and fully phosphorothiolated oligonucleo-
tides (Exiqon, Vedbaek, Denmark). LNA-anti-miR-sc and LNA-
anti-miR-449a were directly applied to hBMSCs. After 48 hr, cells
were harvested, and chondrogenic differentiation was induced by
micromass culture. A list of all miRNA sequences used is provided
in Table S1.
Real-Time qPCR
Total RNA was extracted from harvested cells using TRIzol Reagent
(Invitrogen, Carlsbad, CA, USA), and cDNA was synthesized for
real-time qPCR (Applied Biosystems, Foster City, CA, USA). miR-
speciﬁc real-time qPCR was performed according to guidelines of a
manufacturer, and U6 small nuclear RNA (snRNA) was used as a
control to quantify miRNAs (Clontech, Palo Alto, CA, USA). A list
of all primer sequences used is provided in Table S2.
Western Blot Analysis
For protein extraction, cells were harvested and lysed in lysis
buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1% tergitol-type
NP-40 [NP-40], and 0.1% SDS) and processed as previously
described.34 The primary antibodies used targeted LEF1, SIRT1,
SOX9, and GAPDH (all from Santa Cruz Biotechnology, USA).
In Vivo Surgical Induction of an Acute Defect Model in Rats
The Committee on the Ethics of Animal Experiments of Yonsei Uni-
versity College of Medicine approved all animal experiments and pro-
tocols (permit no. 2015-0168). Male Sprague-Dawley rats (n = 7 per
group) at 12 weeks of age were anaesthetized with an intra-peritonealodel
afranin O staining andMT staining of histological sections of articular cartilage. Scale
nd OARSI scoring systems (left and right panels, respectively). (D) Left: COL2A1 and
erstaining. Scale bar, 50 mm (original magnification40). Right: quantification of IHC
defect group. **p < 0.01; ***p < 0.001 (n = 7 for each group).
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www.moleculartherapy.orginjection of Zoletil (30 mg/kg) and Rompun (10 mg/kg). To expose
the rat knee joint, we made a para-patellar incision using a surgical
blade. After lateral dislocation of the patella, we created an osteochon-
dral defect (2.0 mm in diameter and 1.5 mm in depth) on the patellar
groove of the distal femur using a trephine burr. Next, scaffolds were
inserted into the osteochondral defect sites, and we randomly allo-
cated the animals into four groups as follows: (1) untreated defect,
(2) hBMSCs only, (3) hBMSCs with LNA-anti-miR-sc, and (4)
hBMSCs with LNA-anti-miR-449a. Fibrin gel (Greenplast Kit; Green
Cross, Seoul, Korea) was used as a scaffold according to the manufac-
turer’s instructions. Finally, the incision site was closed with Vicryl,
andMetacam (1 mg/kg) was used as an analgesic. Rats were sacriﬁced
4 and 8 weeks after surgery, and the knee joints were harvested.
In Vivo DMM in Rats and Intra-articular Injection of LNA-Anti-
miR-449a
To establish a rat model of OA, we prepared the right knees of
12-week-old male Sprague-Dawley rats (n = 7 per group) for DMM
surgery according to a previous study.60 In brief, the medial meniscus
(MM) and medial meniscotibial ligament (MMTL) were opened
following the dissection of the fat pad. Then, the menisci were devi-
talized due to transection of the MMTL with no. 11 blade, and the
wound was closed with 3-0 Vicryl.60 Animals were randomly allo-
cated into four groups as follows: DMM without treatment (defect),
DMM with PBS, DMM with LNA-anti-miR-sc, and DMM with
LNA-anti-miR-449a. Intra-articular injections of 50 mL of PBS,
LNA-anti-miR-sc (100 nM), and LNA-anti-miR-449a (100 nM)
were performed 8 weeks after DMM surgery twice a week and imme-
diately following DMM surgery twice a week for 12 weeks.55,61 At 8,
12, and 16 weeks post-DMM, the rats were sacriﬁced under anesthesia
and knee joints were harvested.
Histological and IHC Analysis
Knee joints were ﬁxed with 3.7% formaldehyde, decalciﬁed
with Calci-Clear Rapid (National Diagnostics, Atlanta, GA, USA),
embedded in parafﬁn, and cut into 100-mm sections. For histological
analysis, the sections were deparafﬁnized in xylene and serially rehy-
drated in ethanol. The sections were sequentially stained with MT,
H&E, Alcian blue and safranin O staining accrording to conventional
protocols. To evaluate the histological assessment of the acute defect
model, we used the O’Driscoll scoring system62 and as demonstrated
in Table S3; to evaluate the histological assessment of the OA models,
we used modiﬁed Mankin and OARSI score systems for cartilage
regeneration following as demonstrated in Table S4.63,64 For IHC, pri-
mary antibodies against ACAN, COL2A1, MMP13 (all from Santa
Cruz Biotechnology, USA), and COX2 (BD Biosciences, USA) were
used. All histological results were evaluated fairly by independentFigure 6. Prevention of Cartilage Destruction by LNA-Anti-miR-449a in an OA M
(A) Experimental design for prevention of cartilage degeneration induced by DMM. (B) Re
12weeks after DMM surgery. Scale bar, 200 mm (original magnification10). (C) Histolog
respectively). (D) Left: COL2A1 and ACAN expression on the regenerated cartilage sur
fication40). Right: quantification of IHC analysis. Data are defined asmean ±SD. p valu
each group).blind assessment. The numbers of positively stained cells were calcu-
lated using ImageJ 1.51f software (NIH).
Statistical Analysis
For each experiment, samples were analyzed in triplicate. For com-
parisons of over three groups, we used one-way ANOVA and post
hoc comparison with the Tukey correction. Two-tailed independent
t tests were used for comparisons between two groups. GraphPad
Prism software (version 6.0) was used for statistical analysis. p values
less than 0.05 were considered statistically signiﬁcant. All data are
presented as mean ± SD.
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